Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 480-680-7 | CAS number: 120128-90-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: Toxicokinetic assessment
- Adequacy of study:
- supporting study
- Study period:
- 15. Aug. 2006 - 15. Aug. 2006
- Rationale for reliability incl. deficiencies:
- other: Assessment based on results of GLP toxicology studies, well documented
- Principles of method if other than guideline:
- Assessment based on results of GLP toxicology studies.
- Conclusions:
- Interpretation of results (migrated information): other: No bioaccumulation potential anticipated based on expert judgement
Based on the expected kinetic behavior in the body, FORMAMIDOPROPYLBETAINE will show reduced absorption after oral or dermal administration or after inhalation. FORMAMIDOPROPYLBETAINE will be eliminated from the body via the urine. Accumulation of FORMAMIDOPROPYLBETAINE during prolonged exposure is highly unlikely. Accumulation in fatty tissues is not anticipated. - Executive summary:
TOXICOKINETIC ASSESSMENT OF FORMAMIDOPROPYLBETAINE
Absorption: Although the relatively small molecular size and the high water solubility of the substance indicates that uptake can take place through aqueous pores, the hydrophilic character of the substance (log Po/w: -3.3) will limit this passive diffusion. Furthermore, the ionization of FORMAMIDOPROPYLBETAINE will impair the uptake since compounds need to pass the lipid membranes in the gastrointestinal wall (1). It is therefore unlikely that FORMAMIDOPROPYLBETAINE will be absorbed to a high extent from the gastro-intestinal tract. For risk assessment purposes the oral absorption of FORMAMIDOPROPYLBETAINE is set at 10%. The results of the toxicity studies do not provide reasons to deviate from this proposed oral absorption factor. The high water solubility of FORMAMIDOPROPYLBETAINE indicates that the substance will dissolve in the mucus lining of the respiratory tract and subsequently be absorbed through aqueous pores (taking the molecular weight <200 into account). The hydrophilic character of the substance (log Po/w: -3.3) indicates a limited potential for absorption directly across the respiratory tract epithelium. Although it is unlikely that FORMAMIDOPROPYLBETAINE will be absorbed to a high extent after inhalation via the lungs, for risk assessment purposes the inhalation absorption of FORMAMIDOPROPYLBETAINE is set at 100% as a worst case assumption. FORMAMIDOPROPYLBETAINE being a substance in solution has the potential to be dermally absorbed. The substance however is expected to be too hydrophilic to cross the lipid rich environment of the stratum corneum (miscible with water; log Po/w: -3.3). As the criteria for 10% dermal absorption as given in the TGD (2) (MW > 500 and log Po/w < -1) are not met, 50% dermal absorption of FORMAMIDOPROPYLBETAINE is proposed for risk assessment purposes. The results of the toxicity studies do not provide reasons to deviate from this proposed dermal absorption factor.
Distribution: FORMAMIDOPROPYLBETAINE will show a relatively small volume of distribution. Distribution of FORMAMIDOPROPYLBETAINE will be limited to the extracellular space, because of the ionization in plasma. Therefore, a volume of distribution equaling that of the extracellular space (approx. 12 L) is expected. Accumulation in fatty tissues is not anticipated.
Metabolism and excretion: Absorbed FORMAMIDOPROPYLBETAINE will largely be eliminated in the unchanged form via renal excretion. Renal excretion will be in the non-ionized form only via glomerular filtration. Hence, the flow of urine is important for the maintenance of a concentration gradient, favoring excretion of the non-ionized forms. Glucuronidation and/or sulphation may take place on the carboxylic acid group (3). Because of the small size of the molecule, the conjugates will probably be excreted via the urine.
Conclusion : Based on the expected kinetic behavior in the body, FORMAMIDOPROPYLBETAINE will show reduced absorption after oral or dermal administration or after inhalation. FORMAMIDOPROPYLBETAINE will be eliminated from the body via the urine. Accumulation of FORMAMIDOPROPYLBETAINE during prolonged exposure is highly unlikely. Accumulation in fatty tissues is not anticipated.
References:
1. Martinez MN, Amidon GL. Mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002; 42: 620-43.
2. ECB EU Technical Guidance Document on Risk Assessment, 2003.
3. A Parkinson. In: Casarett and Doull's Toxicology, The basic science of poisons. Sixth edition. Ed. C.D. Klaassen. Chapter 6: Biotransformation of xenobiotics. McGraw-Hili, New York, 2001.
Reference
Absorption : Although the relatively small molecular size and the high water solubility of the substance indicates that uptake can take place through aqueous pores, the hydrophilic character of the substance (log Po/w: -3.3) will limit this passive diffusion. Furthermore, the ionization of FORMAMIDOPROPYLBETAINE will impair the uptake since compounds need to pass the lipid membranes in the gastrointestinal wall (1). It is therefore unlikely that FORMAMIDOPROPYLBETAINE will be absorbed to a high extent from the gastro-intestinal tract. For risk assessment purposes the oral absorption of FORMAMIDOPROPYLBETAINE is set at 10%. The results of the toxicity studies do not provide reasons to deviate from this proposed oral absorption factor. The high water solubility of FORMAMIDOPROPYLBETAINE indicates that the substance will dissolve in the mucus lining of the respiratory tract and subsequently be absorbed through aqueous pores (taking the molecular weight <200 into account). The hydrophilic character of the substance (log Po/w: -3.3) indicates a limited potential for absorption directly across the respiratory tract epithelium. Although it is unlikely that FORMAMIDOPROPYLBETAINE will be absorbed to a high extent after inhalation via the lungs, for risk assessment purposes the inhalation absorption of FORMAMIDOPROPYLBETAINE is set at 100% as a worst case assumption. FORMAMIDOPROPYLBETAINE being a substance in solution has the potential to be dermally absorbed. The substance however is expected to be too hydrophilic to cross the lipid rich environment of the stratum corneum (miscible with water; log Po/w: -3.3). As the criteria for 10% dermal absorption as given in the TGD (2) (MW > 500 and log Po/w < -1) are not met, 50% dermal absorption of FORMAMIDOPROPYLBETAINE is proposed for risk assessment purposes. The results of the toxicity studies do not provide reasons to deviate from this proposed dermal absorption factor.
Distribution : FORMAMIDOPROPYLBETAINE will show a relatively small volume of distribution. Distribution of FORMAMIDOPROPYLBETAINE will be limited to the extracellular space, because of the ionization in plasma. Therefore, a volume of distribution equaling that of the extracellular space (approx. 12 L) is expected. Accumulation in fatty tissues is not anticipated.
Metabolism and excretion : Absorbed FORMAMIDOPROPYLBETAINE will largely be eliminated in the unchanged form via renal excretion. Renal excretion will be in the non-ionized form only via glomerular filtration. Hence, the flow of urine is important for the maintenance of a concentration gradient, favoring excretion of the non-ionized forms. Glucuronidation and/or sulphation may take place on the carboxylic acid group (3). Because of the small size of the molecule, the conjugates will probably be excreted via the urine.
References:
1. Martinez MN, Amidon GL. Mechanistic approach to understanding the factors affecting
drug absorption: a review of fundamentals. J Clin Pharmacol 2002; 42: 620-43.
2. ECB EU Technical Guidance Document on Risk Assessment, 2003.
3. A Parkinson. In: Casarett and Doull's Toxicology, The basic science of poisons. Sixth
edition. Ed. C.D. Klaassen. Chapter 6: Biotransformation of xenobiotics. McGraw-Hili,
New York, 2001.
Description of key information
Short description of key information on bioaccumulation potential result:
Based on the expected kinetic behavior in the body, FORMAMIDOPROPYLBETAINE will show reduced absorption after oral or dermal administration or after inhalation. FORMAMIDOPROPYLBETAINE will be eliminated from the body via the urine. Accumulation of FORMAMIDOPROPYLBETAINE during prolonged exposure is highly unlikely. Accumulation in fatty tissues is not anticipated.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 10
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
TOXICOKINETIC ASSESSMENT OF FORMAMIDOPROPYLBETAINE
Absorption: Although the relatively small molecular size and the high water solubility of the substance indicates that uptake can take place through aqueous pores, the hydrophilic character of the substance (log Po/w: -3.3) will limit this passive diffusion. Furthermore, the ionization of FORMAMIDOPROPYLBETAINE will impair the uptake since compounds need to pass the lipid membranes in the gastrointestinal wall (1). It is therefore unlikely that FORMAMIDOPROPYLBETAINE will be absorbed to a high extent from the gastro-intestinal tract. For risk assessment purposes the oral absorption of FORMAMIDOPROPYLBETAINE is set at 10%. The results of the toxicity studies do not provide reasons to deviate from this proposed oral absorption factor. The high water solubility of FORMAMIDOPROPYLBETAINE indicates that the substance will dissolve in the mucus lining of the respiratory tract and subsequently be absorbed through aqueous pores (taking the molecular weight <200 into account). The hydrophilic character of the substance (log Po/w: -3.3) indicates a limited potential for absorption directly across the respiratory tract epithelium. Although it is unlikely that FORMAMIDOPROPYLBETAINE will be absorbed to a high extent after inhalation via the lungs, for risk assessment purposes the inhalation absorption of FORMAMIDOPROPYLBETAINE is set at 100% as a worst case assumption. FORMAMIDOPROPYLBETAINE being a substance in solution has the potential to be dermally absorbed. The substance however is expected to be too hydrophilic to cross the lipid rich environment of the stratum corneum (miscible with water; log Po/w: -3.3). As the criteria for 10% dermal absorption as given in the TGD (2) (MW > 500 and log Po/w < -1) are not met, 50% dermal absorption of FORMAMIDOPROPYLBETAINE is proposed for risk assessment purposes. The results of the toxicity studies do not provide reasons to deviate from this proposed dermal absorption factor.
Distribution: FORMAMIDOPROPYLBETAINE will show a relatively small volume of distribution. Distribution of FORMAMIDOPROPYLBETAINE will be limited to the extracellular space, because of the ionization in plasma. Therefore, a volume of distribution equaling that of the extracellular space (approx. 12 L) is expected. Accumulation in fatty tissues is not anticipated.
Metabolism and excretion: Absorbed FORMAMIDOPROPYLBETAINE will largely be eliminated in the unchanged form via renal excretion. Renal excretion will be in the non-ionized form only via glomerular filtration. Hence, the flow of urine is important for the maintenance of a concentration gradient, favoring excretion of the non-ionized forms. Glucuronidation and/or sulphation may take place on the carboxylic acid group (3). Because of the small size of the molecule, the conjugates will probably be excreted via the urine.
Conclusion: Based on the expected kinetic behavior in the body, FORMAMIDOPROPYLBETAINE will show reduced absorption after oral or dermal administration or after inhalation. FORMAMIDOPROPYLBETAINE will be eliminated from the body via the urine. Accumulation of FORMAMIDOPROPYLBETAINE during prolonged exposure is highly unlikely. Accumulation in fatty tissues is not anticipated.
References:
1. Martinez MN, Amidon GL. Mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002; 42: 620-43.
2. ECB EU Technical Guidance Document on Risk Assessment, 2003.
3. A Parkinson. In: Casarett and Doull's Toxicology, The basic science of poisons. Sixth edition. Ed. C.D. Klaassen. Chapter 6: Biotransformation of xenobiotics. McGraw-Hili, New York, 2001.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.